{"entity":{"type":"insider","cik":"0001719960","url":"/insider/0001719960","json_url":"/insider/0001719960.json","name":"MPM ONCOLOGY INNOVATIONS FUND LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":31,"n_filings":12,"first":"2021-05-06","last":"2026-01-14","span_basis":"filed_date"},"name_variants":[{"name":"MPM ONCOLOGY INNOVATIONS FUND LP","source":"filing","n_filings":12,"first_seen":"2021-05-06","last_seen":"2026-01-14"}],"transactions":[{"id":6118631,"accession":"0001231919-26-000057","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001231919-26-000057","line_url":"/filing/0001231919-26-000057#line-4","is_derivative":false,"issuer_cik":"0001134657","issuer_name":"Aktis Oncology, Inc.","issuer_ticker":"AKTS","issuer_name_source":null,"issuer_url":"/issuer/0001134657","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BioVentures 2018 LLC; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; EVNIN LUKE; MPM BioVentures 2018 GP LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1112777.0,"shares_display":"1,112,777","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":20029986.0,"total_display":"20,029,986.00","total_whole":"20,029,986","shares_owned_after":10260064.0,"shares_owned_after_display":"10,260,064","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-12","filed_date":"2026-01-14","scope":"insider"},{"id":4070094,"accession":"0001231919-25-000574","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000574","line_url":"/filing/0001231919-25-000574#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM ONCOLOGY INNOVATIONS FUND LP","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":83230.0,"shares_display":"83,230","price_per_share":0.97,"price_display":"0.97","price_state":"stated","total_value":80733.1,"total_display":"80,733.10","total_whole":"80,733","shares_owned_after":4784111.0,"shares_owned_after_display":"4,784,111","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-04","filed_date":"2025-12-04","scope":"insider"},{"id":4070089,"accession":"0001231919-25-000574","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000574","line_url":"/filing/0001231919-25-000574#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM ONCOLOGY INNOVATIONS FUND LP","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57225.0,"shares_display":"57,225","price_per_share":0.87,"price_display":"0.87","price_state":"stated","total_value":49785.75,"total_display":"49,785.75","total_whole":"49,786","shares_owned_after":4867341.0,"shares_owned_after_display":"4,867,341","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-03","filed_date":"2025-12-04","scope":"insider"},{"id":4070080,"accession":"0001231919-25-000574","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000574","line_url":"/filing/0001231919-25-000574#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM ONCOLOGY INNOVATIONS FUND LP","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":59277.0,"shares_display":"59,277","price_per_share":0.89,"price_display":"0.89","price_state":"stated","total_value":52756.53,"total_display":"52,756.53","total_whole":"52,757","shares_owned_after":4924566.0,"shares_owned_after_display":"4,924,566","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-02","filed_date":"2025-12-04","scope":"insider"},{"id":4315615,"accession":"0001231919-25-000564","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000564","line_url":"/filing/0001231919-25-000564#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Innovations Fund GP LLC; MPM BioImpact LLC; UBS Oncology Impact Fund L.P.; MPM ASSET MANAGEMENT LLC; MPM ONCOLOGY INNOVATIONS FUND LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Innovations Fund GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60917.0,"shares_display":"60,917","price_per_share":0.94,"price_display":"0.94","price_state":"stated","total_value":57261.98,"total_display":"57,261.98","total_whole":"57,262","shares_owned_after":4983843.0,"shares_owned_after_display":"4,983,843","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-01","filed_date":"2025-12-01","scope":"insider"},{"id":4315605,"accession":"0001231919-25-000564","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000564","line_url":"/filing/0001231919-25-000564#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Innovations Fund GP LLC; MPM BioImpact LLC; UBS Oncology Impact Fund L.P.; MPM ASSET MANAGEMENT LLC; MPM ONCOLOGY INNOVATIONS FUND LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Innovations Fund GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20277.0,"shares_display":"20,277","price_per_share":0.99,"price_display":"0.99","price_state":"stated","total_value":20074.23,"total_display":"20,074.23","total_whole":"20,074","shares_owned_after":5044760.0,"shares_owned_after_display":"5,044,760","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-28","filed_date":"2025-12-01","scope":"insider"},{"id":4315600,"accession":"0001231919-25-000564","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000564","line_url":"/filing/0001231919-25-000564#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Innovations Fund GP LLC; MPM BioImpact LLC; UBS Oncology Impact Fund L.P.; MPM ASSET MANAGEMENT LLC; MPM ONCOLOGY INNOVATIONS FUND LP; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Innovations Fund GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60733.0,"shares_display":"60,733","price_per_share":0.98,"price_display":"0.98","price_state":"stated","total_value":59518.34,"total_display":"59,518.34","total_whole":"59,518","shares_owned_after":5065037.0,"shares_owned_after_display":"5,065,037","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-26","filed_date":"2025-12-01","scope":"insider"},{"id":4049500,"accession":"0001231919-25-000550","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000550","line_url":"/filing/0001231919-25-000550#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42533.0,"shares_display":"42,533","price_per_share":0.92,"price_display":"0.92","price_state":"stated","total_value":39130.36,"total_display":"39,130.36","total_whole":"39,130","shares_owned_after":5125770.0,"shares_owned_after_display":"5,125,770","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-25","filed_date":"2025-11-25","scope":"insider"},{"id":4049499,"accession":"0001231919-25-000550","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000550","line_url":"/filing/0001231919-25-000550#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":88802.0,"shares_display":"88,802","price_per_share":0.98,"price_display":"0.98","price_state":"stated","total_value":87025.96,"total_display":"87,025.96","total_whole":"87,026","shares_owned_after":5168303.0,"shares_owned_after_display":"5,168,303","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-25","scope":"insider"},{"id":4049498,"accession":"0001231919-25-000550","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000550","line_url":"/filing/0001231919-25-000550#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64331.0,"shares_display":"64,331","price_per_share":0.83,"price_display":"0.83","price_state":"stated","total_value":53394.73,"total_display":"53,394.73","total_whole":"53,395","shares_owned_after":5257105.0,"shares_owned_after_display":"5,257,105","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-21","filed_date":"2025-11-25","scope":"insider"},{"id":5000481,"accession":"0001231919-25-000533","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000533","line_url":"/filing/0001231919-25-000533#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"UBS Oncology Impact Fund L.P.; MPM BioImpact LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM ASSET MANAGEMENT LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Innovations Fund GP LLC","owner_display_name":"UBS Oncology Impact Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41152.0,"shares_display":"41,152","price_per_share":0.89,"price_display":"0.89","price_state":"stated","total_value":36625.28,"total_display":"36,625.28","total_whole":"36,625","shares_owned_after":5321436.0,"shares_owned_after_display":"5,321,436","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-20","filed_date":"2025-11-20","scope":"insider"},{"id":5000478,"accession":"0001231919-25-000533","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000533","line_url":"/filing/0001231919-25-000533#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"UBS Oncology Impact Fund L.P.; MPM BioImpact LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM ASSET MANAGEMENT LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Innovations Fund GP LLC","owner_display_name":"UBS Oncology Impact Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":66324.0,"shares_display":"66,324","price_per_share":0.94,"price_display":"0.94","price_state":"stated","total_value":62344.56,"total_display":"62,344.56","total_whole":"62,345","shares_owned_after":5362588.0,"shares_owned_after_display":"5,362,588","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-19","filed_date":"2025-11-20","scope":"insider"},{"id":5000472,"accession":"0001231919-25-000533","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000533","line_url":"/filing/0001231919-25-000533#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"UBS Oncology Impact Fund L.P.; MPM BioImpact LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM ASSET MANAGEMENT LLC; Oncology Impact Fund (Cayman) Management L.P.; MPM Oncology Innovations Fund GP LLC","owner_display_name":"UBS Oncology Impact Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52627.0,"shares_display":"52,627","price_per_share":0.93,"price_display":"0.93","price_state":"stated","total_value":48943.11,"total_display":"48,943.11","total_whole":"48,943","shares_owned_after":5428912.0,"shares_owned_after_display":"5,428,912","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-20","scope":"insider"},{"id":5072316,"accession":"0001231919-25-000507","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000507","line_url":"/filing/0001231919-25-000507#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57061.0,"shares_display":"57,061","price_per_share":0.95,"price_display":"0.95","price_state":"stated","total_value":54207.95,"total_display":"54,207.95","total_whole":"54,208","shares_owned_after":5481539.0,"shares_owned_after_display":"5,481,539","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-17","filed_date":"2025-11-17","scope":"insider"},{"id":5072311,"accession":"0001231919-25-000507","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000507","line_url":"/filing/0001231919-25-000507#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61640.0,"shares_display":"61,640","price_per_share":0.93,"price_display":"0.93","price_state":"stated","total_value":57325.2,"total_display":"57,325.20","total_whole":"57,325","shares_owned_after":5538600.0,"shares_owned_after_display":"5,538,600","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-14","filed_date":"2025-11-17","scope":"insider"},{"id":5072306,"accession":"0001231919-25-000507","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000507","line_url":"/filing/0001231919-25-000507#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":90951.0,"shares_display":"90,951","price_per_share":0.98,"price_display":"0.98","price_state":"stated","total_value":89131.98,"total_display":"89,131.98","total_whole":"89,132","shares_owned_after":5600240.0,"shares_owned_after_display":"5,600,240","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-13","filed_date":"2025-11-17","scope":"insider"},{"id":4105372,"accession":"0001231919-25-000459","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001231919-25-000459","line_url":"/filing/0001231919-25-000459#line-4","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; MPM ONCOLOGY INNOVATIONS FUND LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40669.0,"shares_display":"40,669","price_per_share":1.09,"price_display":"1.09","price_state":"stated","total_value":44329.21,"total_display":"44,329.21","total_whole":"44,329","shares_owned_after":5691191.0,"shares_owned_after_display":"5,691,191","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-12","filed_date":"2025-11-12","scope":"insider"},{"id":4105367,"accession":"0001231919-25-000459","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000459","line_url":"/filing/0001231919-25-000459#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; MPM ONCOLOGY INNOVATIONS FUND LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55810.0,"shares_display":"55,810","price_per_share":1.14,"price_display":"1.14","price_state":"stated","total_value":63623.4,"total_display":"63,623.40","total_whole":"63,623","shares_owned_after":5731860.0,"shares_owned_after_display":"5,731,860","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-11","filed_date":"2025-11-12","scope":"insider"},{"id":4105362,"accession":"0001231919-25-000459","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000459","line_url":"/filing/0001231919-25-000459#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; MPM ONCOLOGY INNOVATIONS FUND LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48570.0,"shares_display":"48,570","price_per_share":1.18,"price_display":"1.18","price_state":"stated","total_value":57312.6,"total_display":"57,312.60","total_whole":"57,313","shares_owned_after":5787670.0,"shares_owned_after_display":"5,787,670","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-10","filed_date":"2025-11-12","scope":"insider"},{"id":4105358,"accession":"0001231919-25-000459","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000459","line_url":"/filing/0001231919-25-000459#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM BioImpact LLC; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; MPM ONCOLOGY INNOVATIONS FUND LP; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM BioImpact LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":68480.0,"shares_display":"68,480","price_per_share":1.11,"price_display":"1.11","price_state":"stated","total_value":76012.8,"total_display":"76,012.80","total_whole":"76,013","shares_owned_after":5836240.0,"shares_owned_after_display":"5,836,240","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-07","filed_date":"2025-11-12","scope":"insider"},{"id":5072299,"accession":"0001231919-25-000439","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000439","line_url":"/filing/0001231919-25-000439#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; MPM Oncology Innovations Fund GP LLC; MPM ASSET MANAGEMENT LLC; MPM BioImpact LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54452.0,"shares_display":"54,452","price_per_share":1.21,"price_display":"1.21","price_state":"stated","total_value":65886.92,"total_display":"65,886.92","total_whole":"65,887","shares_owned_after":5904720.0,"shares_owned_after_display":"5,904,720","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-06","filed_date":"2025-11-06","scope":"insider"},{"id":5072294,"accession":"0001231919-25-000439","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000439","line_url":"/filing/0001231919-25-000439#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; MPM Oncology Innovations Fund GP LLC; MPM ASSET MANAGEMENT LLC; MPM BioImpact LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47950.0,"shares_display":"47,950","price_per_share":1.22,"price_display":"1.22","price_state":"stated","total_value":58499.0,"total_display":"58,499.00","total_whole":"58,499","shares_owned_after":5959172.0,"shares_owned_after_display":"5,959,172","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-05","filed_date":"2025-11-06","scope":"insider"},{"id":5072291,"accession":"0001231919-25-000439","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000439","line_url":"/filing/0001231919-25-000439#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; Oncology Impact Fund (Cayman) Management L.P.; UBS Oncology Impact Fund L.P.; MPM Oncology Innovations Fund GP LLC; MPM ASSET MANAGEMENT LLC; MPM BioImpact LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":140488.0,"shares_display":"140,488","price_per_share":1.22,"price_display":"1.22","price_state":"stated","total_value":171395.36,"total_display":"171,395.36","total_whole":"171,395","shares_owned_after":6007122.0,"shares_owned_after_display":"6,007,122","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-04","filed_date":"2025-11-06","scope":"insider"},{"id":4374746,"accession":"0001231919-25-000404","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000404","line_url":"/filing/0001231919-25-000404#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM BioImpact LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":94063.0,"shares_display":"94,063","price_per_share":1.29,"price_display":"1.29","price_state":"stated","total_value":121341.27,"total_display":"121,341.27","total_whole":"121,341","shares_owned_after":6147610.0,"shares_owned_after_display":"6,147,610","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-03","filed_date":"2025-11-03","scope":"insider"},{"id":4374743,"accession":"0001231919-25-000404","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000404","line_url":"/filing/0001231919-25-000404#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM BioImpact LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114044.0,"shares_display":"114,044","price_per_share":1.28,"price_display":"1.28","price_state":"stated","total_value":145976.32,"total_display":"145,976.32","total_whole":"145,976","shares_owned_after":6241673.0,"shares_owned_after_display":"6,241,673","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-31","filed_date":"2025-11-03","scope":"insider"},{"id":4374740,"accession":"0001231919-25-000404","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000404","line_url":"/filing/0001231919-25-000404#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM ONCOLOGY INNOVATIONS FUND LP; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; Oncology Impact Fund (Cayman) Management L.P.; MPM BioImpact LLC","owner_display_name":"MPM ONCOLOGY INNOVATIONS FUND LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":86936.0,"shares_display":"86,936","price_per_share":1.43,"price_display":"1.43","price_state":"stated","total_value":124318.48,"total_display":"124,318.48","total_whole":"124,318","shares_owned_after":6355717.0,"shares_owned_after_display":"6,355,717","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-30","filed_date":"2025-11-03","scope":"insider"},{"id":4274131,"accession":"0001231919-25-000373","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000373","line_url":"/filing/0001231919-25-000373#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP; MPM BioImpact LLC","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":134240.0,"shares_display":"134,240","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":208072.0,"total_display":"208,072.00","total_whole":"208,072","shares_owned_after":6442653.0,"shares_owned_after_display":"6,442,653","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-29","filed_date":"2025-10-29","scope":"insider"},{"id":4274127,"accession":"0001231919-25-000373","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000373","line_url":"/filing/0001231919-25-000373#line-2","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP; MPM BioImpact LLC","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69068.0,"shares_display":"69,068","price_per_share":1.64,"price_display":"1.64","price_state":"stated","total_value":113271.52,"total_display":"113,271.52","total_whole":"113,272","shares_owned_after":6576893.0,"shares_owned_after_display":"6,576,893","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-29","scope":"insider"},{"id":4274120,"accession":"0001231919-25-000373","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000373","line_url":"/filing/0001231919-25-000373#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP; MPM BioImpact LLC","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":72709.0,"shares_display":"72,709","price_per_share":1.72,"price_display":"1.72","price_state":"stated","total_value":125059.48,"total_display":"125,059.48","total_whole":"125,059","shares_owned_after":6645961.0,"shares_owned_after_display":"6,645,961","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-27","filed_date":"2025-10-29","scope":"insider"},{"id":4467051,"accession":"0001415889-25-011569","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-011569","line_url":"/filing/0001415889-25-011569#line-1","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"Oncology Impact Fund (Cayman) Management L.P.; MPM ASSET MANAGEMENT LLC; MPM ONCOLOGY INNOVATIONS FUND LP; UBS Oncology Impact Fund L.P.; MPM BioImpact LLC; MPM Oncology Innovations Fund GP LLC","owner_display_name":"Oncology Impact Fund (Cayman) Management L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4386.0,"shares_display":"4,386","price_per_share":1.05,"price_display":"1.05","price_state":"stated","total_value":4605.3,"total_display":"4,605.30","total_whole":"4,605","shares_owned_after":6718670.0,"shares_owned_after_display":"6,718,670","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-27","filed_date":"2025-04-30","scope":"insider"},{"id":5490784,"accession":"0001209191-21-030625","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-030625","line_url":"/filing/0001209191-21-030625#line-3","is_derivative":false,"issuer_cik":"0001134655","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001134655","owner_cik":null,"owner_name":"MPM Oncology Innovations Fund GP LLC; UBS Oncology Impact Fund L.P.; MPM ONCOLOGY INNOVATIONS FUND LP; GADICKE ANSBERT; MPM Oncology Impact Management LP; MPM Oncology Impact Management GP LLC; Oncology Impact Fund (Cayman) Management L.P.","owner_display_name":"MPM Oncology Innovations Fund GP LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":245000.0,"shares_display":"245,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3920000.0,"total_display":"3,920,000.00","total_whole":"3,920,000","shares_owned_after":6672183.0,"shares_owned_after_display":"6,672,183","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-04","filed_date":"2021-05-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002035832","name":"Aktis Oncology, Inc.","url":"/issuer/0002035832","role":"Ten percent owner","n_filings":1,"first_seen":"2026-01-14","last_seen":"2026-01-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001785530","name":"Werewolf Therapeutics, Inc.","url":"/issuer/0001785530","role":"Ten percent owner, Other","n_filings":11,"first_seen":"2021-05-06","last_seen":"2025-12-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001719960","retrieved_at":"2026-08-22T19:30:19+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}